Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy

Дата публикации: 18-06-2026 00:00:00

This systematic review and meta-analysis estimates the frequency of reported second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy and evaluates whether study-level characteristics and reporting definitions influence observed estimates.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
2	Cardiotoxicity of Immune Checkpoint Inhibitors	0	8	01-10-2024
3	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
4	Total Thyroidectomy vs Lobectomy for Sporadic Medullary Thyroid Cancer	0	7.74	01-04-2026
5	Equity and Cancer Survival Among Veterans Health Administration Patients	0	7	02-07-2026
6	UC Irvine study identifies serious infection risks linked to targeted cancer therapies	0	7	02-06-2026
7	Three-Body Problem at Digital Frontiers	0	5	25-06-2026
8	Classic Hodgkin Lymphoma: A Review	0	7.97	03-08-2026
9	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
10	Error in Open Access License	0	5	18-06-2026

Классификация: Общество. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.